BioNTech has hired one of Novartis’ radioligand therapy leaders as its new chief commercial officer, as the company looks to pivot from reliance on its Covid franchise and become a multi-product company.
Meanwhile, the German drugmaker terminated an early-phase study that combines one of its cancer vaccines with Sanofi and Regeneron’s Libtayo in prostate cancer, as it touted its wider oncology pipeline on Wednesday.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.